Nevertheless, risk scoring systems, vascular imaging modalities, and long-term clinical outcomes, such as mortality and major adverse cardiovascular events, in larger, prospective cohorts with more diverse populations, and longitudinal designs must be carried out to confirm our findings and to delineate the mechanistic pathways via which sclerostin is related to PAD. The gene discussed is SOST; the disease is peripheral arterial disease.